HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
A Multicenter, Open-label, Phase I Study to Evaluate the Safety, Pharmacokinetics, and
Preliminary Efficacy of HMPL-760 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's
Lymphoma